Barosi, Giovanni

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine

Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 1,825

Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis

Ciurea, S. O., Merchant, D., Mahmud, N., Ishii, T., Zhao, Y., Hu, W., Bruno, E., Barosi, G., Xu, M., & Hoffman, R. (2007) · Blood

Myeloproliferative Neoplasms: Diagnosis and TreatmentPlatelet Disorders and Treatments

Cited by 213

Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis

Cazzola, M., Ponchio, L., de Benedetti, F., Ravelli, A., Rosti, V, Beguin, Y., Invernizzi, R., Barosi, G., & Martini, A. (1996) · Blood

Iron Metabolism and DisordersErythropoietin and Anemia Treatment

Cited by 197

Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy

Harrison, C. N., Mesa, R. A., Kiladjian, J., Al‐Ali, H., Gisslinger, H., Knoops, L., Squier, M., Sirulnik, A., Mendelson, E., Zhou, X., et al. (2013) · British Journal of Haematology

Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 90

Involvement of TGF 1 in autocrine regulation of proplatelet formation in healthy subjects and patients with primary myelofibrosis

Badalucco, S., Di Buduo, C. A., Campanelli, R., Pallotta, I., Catarsi, P., Rosti, V., Kaplan, D. L., Barosi, G., Massa, M., & Balduini, A. (2013) · Haematologica

Platelet Disorders and TreatmentsMyeloproliferative Neoplasms: Diagnosis and Treatment

Cited by 37